Nymex's data vendors are redistributing Level 1 trading data, including last sale, high/low, open/close, volume, open interest and settlement date, from the DME to Nymex members. The DME is initially ...

月曜日、ベアードは特殊医薬品会社であるアイポイント・ファーマシューティカルズ（NASDAQ:EYPT）の目標株価を、以前の38 ...

A 4D Molecular Therapeutics, Inc. phase 2 PRISM study indicated that there was an 89% reduction in annualized injections when Wet-AMD patients were given a high dose of 4D-150; Phase 3 trial ...

EyePoint Pharmaceuticals' lead product, EYP-1901, shows promising phase 2 results for wet AMD and DME, with one phase 3 trial ongoing and one more planned for 2025. EYP-1901 demonstrated strong safety ...

これまでの連載で、BYODを含めた自由度の高いスマートデバイス利用と、企業の要求する高いセキュリティを両立させる「DME」メリットをレポートしてきた。今回は、実際に企業がDMEの導入を考えた場合、どのような作業が必要になるのか、具体的な内容に ...

Across all DME patients dosed to date, 4D-150 continues to be well tolerated with no intraocular inflammation observed at any timepoint or dose level 3E10 vg/eye demonstrated strong signals of ...

These gains were seen in patients that are part of the 40-50% of DME patients that suboptimally respond to standard of care ant-VEGF therapy Leuven, BELGIUM, Boston, MA, US – 14 February 2022 – 8.00 ...

4D Molecular Therapeutics reports positive interim data for 4D-150 in wet AMD and DME, with strong financial position and strategic focus. 4D Molecular Therapeutics announced positive interim data for ...

MIAMI LAKES, FL--(Marketwire -08/29/12)- Altegra Health, Inc., a leading provider of technology-enabled revenue management services to healthcare organizations, today announced that it is among the ...